Bicyclic nitroimidazole-substituted phenyl oxazolidinones

US7666864B2 · kind B2 · utility

Assignee

• The Global Alliance for TB Drug Development, Inc. · US

Inventors

• Charles Z. Ding · San Mateo, US
• Genliang Lu · Winchester, US
• Keith Combrink · Wallingford, US
• Dianjun CHEN · Houston, US
• Minsoo Song · Dobbs Ferry, US
• Jiancheng Wang · Beijing, CN
• Zhenkun Ma · Westfield, US
• Brian Desmond Palmer · Auckland, NZ
• Adrian Blaser · Auckland, NZ
• Andrew Thompson
• Iveta Kmentova · Dunajská Streda, SK
• Hamish Scott Sutherland · Auckland, NZ
• William Alexander Denny · Beachlands, NZ

Key dates

• Filing date: Mar 25, 2009
• Grant date: Feb 23, 2010
• Expiry date: Mar 25, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.